4′-methoxy-[1,1′-biphenyl]-4-carbonyl chloride | 67132-14-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4′-methoxy-[1,1′-biphenyl]-4-carbonyl chloride
• 英文别名: 4'-methoxy[1,1'-biphenyl]-4-carboxylic acid chloride；4'-methoxy-[1,1'-biphenyl]-4-carbonyl chloride；4'-methoxybiphenylcarbonyl chloride；4'-methoxy-biphenyl-4-carbonyl chloride；4'-Methoxy-biphenyl-4-carbonylchlorid；4-acetylphenyl 4'-methoxybiphenyl-4-carboxylate；4-(4-methoxyphenyl)benzoyl chloride
• CAS: 67132-14-3
• 化学式: C₁₄H₁₁ClO₂
• 分子量: 246.693
• InChiKey: SKWKKEPLQSGOCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4′-methoxy-[1,1′-biphenyl]-4-carbonyl chloride 在 lithium aluminium tetrahydride 、 氯化亚砜 、 乙醚 、 氯仿 、 丙酮 作用下， 生成 4-(4-methoxyphenyl)phenylacetonitrile
  参考文献：
  名称：

  有机分子的电子光谱及其解释。第一部分共轭体系末端甲基和取代甲基对K带的影响

  摘要：

  DOI：

  10.1039/jr9550002557
• 作为产物：
  描述：

  1-(4-甲氧基-联苯-4-基)-乙酮 在 sodium hydroxide 、 氯化亚砜 、 溴 作用下， 生成 4′-methoxy-[1,1′-biphenyl]-4-carbonyl chloride
  参考文献：
  名称：

  Mesogenic Biphenyl Derivatives with Azo and Ester Central Linkage

  摘要：

  Biphenyl nucleus comprises one of the most interesting research areas in the study of relations between chemical constitution and mesomorphic properties. Few biphenyl derivatives with azo and ester central linkage having following general formula have been synthesized and their mesomorphic properties were evaluated.[GRAPHICS]Where R= -H, -OCH3, R' = -CH3, -OCH5, -OC2H5, -OC4H9 X=-H, -Br. All the synthesized compounds were characterized by elemental analysis and spectroscopic methods.

  DOI：

  10.1080/10587250108025047

文献信息

• 4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators
  作者：Nicola Antonio Colabufo、Francesco Berardi、Mariangela Cantore、Maria Grazia Perrone、Marialessandra Contino、Carmela Inglese、Mauro Niso、Roberto Perrone、Amalia Azzariti、Grazia Maria Simone

  DOI：10.1016/j.bmc.2008.01.055

  日期：2008.4.1

  this series whilst the presence of hydroxy or methoxy substituents seems to be negligible. In the naphthyl series, both the basicity and the presence of H-bond donor or acceptor groups seem to be negligible. Moreover, the lipophilicity did not influence the P-gp inhibition activity of each series. Specific biological assays have been carried out to establish the P-gp interacting mechanism of tested

  从铅化合物1（EC（50）= 1.64 microM）开始，其非碱性核已在构象上受到4-联苯和2-萘基部分的限制。在每个系列中，我们研究了H键供体或受体取代基，碱度和亲脂性（clogP）的存在是否与受试化合物的P-gp抑制活性相关。在联苯系列中，衍生物4d表现出最好的结果（EC（50）= 0.05 microM）。发现相应酰胺3d的活性较低（EC（50）= 3.5 microM），确定碱性在该系列中的重要性，而羟基或甲氧基取代基的存在似乎可以忽略不计。在萘系列中，碱度和氢键供体或受体基团的存在似乎都可以忽略不计。此外，亲脂性不影响每个系列的P-gp抑制活性。已经进行了特定的生物学测定，以建立区分底物和抑制剂的被测化合物的P-gp相互作用机制。而且，化合物4d表现出有效的P-gp抑制活性，并且对BCRP泵具有良好的选择性。
• New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20040242572A1

  公开（公告）日：2004-12-02

  The present invention relates to carboxamide compounds of general formula I 1 wherein the groups and residues A, B, W, X, Y, Z, R 1 , R 2 , R 3 and k have the meanings given in claim 1. Moreover the invention relates to process for preparing the above mentioned carboxamides as well as pharmaceutical compositions containing at least one carboxamide according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及具有通式I的羧酰胺化合物 1 其中，A、B、W、X、Y、Z、R 1 、R 2 、R 3 和k的含义如权利要求1中所述。此外，本发明还涉及制备上述羧酰胺的方法以及含有至少一种根据本发明的羧酰胺的药物组合物。由于它们对MCH受体的拮抗活性，根据本发明的药物组合物适合用于治疗代谢紊乱和/或饮食紊乱，特别是肥胖症、厌食症、暴食症、糖尿病。
• Novel and potent small-molecule urotensin II receptor agonists
  作者：Fredrik Lehmann、Erika A. Currier、Bryan Clemons、Lars K. Hansen、Roger Olsson、Uli Hacksell、Kristina Luthman

  DOI：10.1016/j.bmc.2009.04.062

  日期：2009.7

  A series of analogs of the non-peptidic urotensin II receptor agonist N-[1-(4-chlorophenyl)-3-(dimethylamino)propyl]-4-phenylbenzamide (FL104) has been synthesized and evaluated pharmacologically. The enantiomers of the two most potent racemic analogues were obtained from the corresponding diastereomeric mandelic amides. In agreement with previously observed SAR, most of the agonist potency resided

  已经合成了一系列非肽尿紧张素II受体激动剂N- [1-（4-氯苯基）-3-（二甲基氨基）丙基] -4-苯基苯甲酰胺（FL104）的类似物，并进行了药理学评价。两种最有效的外消旋类似物的对映异构体获自相应的非对映体扁桃酰胺。与先前观察到的SAR一致，大多数激动剂效力存在于（S）对映异构体中。新系列中最有效的UII受体激动剂是（S）-N- [3-二甲基氨基-1-（2-萘基丙基）丙基] -4-（4-氯苯基）苯甲酰胺（ 在尿紧张素II处EC 50 = 23 nM受体）。
• Rhodium-Catalyzed Decarbonylative Borylation of Aromatic Thioesters for Facile Diversification of Aromatic Carboxylic Acids
  作者：Hidenori Ochiai、Yuta Uetake、Takashi Niwa、Takamitsu Hosoya

  DOI：10.1002/anie.201611974

  日期：2017.2.20

  efficiently using a rhodium catalyst. The broad functional-group tolerance and mild conditions of the method have allowed for the two-step decarboxylative borylation of a wide range of aromatic carboxylic acids, including commercially available drugs.

  使用铑催化剂有效地实现了芳族硫酯向芳基硼酸酯的转化。该方法具有广泛的官能团耐受性和温和的条件，允许对多种芳香族羧酸（包括市售药物）进行两步脱羧硼基化。
• [EN] MYOSIN LIGHT CHAIN PHOSPHATASE INHIBITORS<br/>[FR] INHIBITEURS DE PHOSPHATASE DE CHAÎNE LÉGÈRE DE MYOSINE
  申请人：UNIV GEORGETOWN

  公开号：WO2009146013A1

  公开（公告）日：2009-12-03

  Novel myosin light chain phosphatase inhibitors, compositions containing them, methods of making and using them, and methods of using fluorescent myosin light chain phosphatase inhibitors are described.

  新型肌球蛋白轻链磷酸酶抑制剂，含有它们的组合物，制备和使用它们的方法，以及使用荧光肌球蛋白轻链磷酸酶抑制剂的方法被描述。